Ranolazine attenuates behavioral signs of neuropathic pain

Behavioural Pharmacology

Volumn 20, Issue 8, 2009, Pages 755-758

  Gould III, Harry J ^a,b   Garrett, Colleen ^c   Donahue, Renee R ^c,e   Paul, Dennis ^a,b   Diamond, Ivan ^d   Taylor, Bradley K ^c,e  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d Gilead Sciences   (United States)

^e UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Allodynia; Hyperalgesia; Na V 1.7; NaV 1.8; Rat; Spared nerve injury

Indexed keywords

ACETIC ACID; RANOLAZINE; SODIUM HYDROXIDE; VOLTAGE GATED SODIUM CHANNEL;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; COLD EXPOSURE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; HYPERALGESIA; MALE; MECHANICAL STIMULATION; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; RAT;

ACETANILIDES; ANIMALS; ATAXIA; BEHAVIOR, ANIMAL; COLD TEMPERATURE; DRUG EVALUATION, PRECLINICAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; NERVOUS SYSTEM DISEASES; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; PIPERAZINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; SODIUM CHANNEL BLOCKERS;

EID: 73949141073     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283323c90     Document Type: Article

References (37)

1. Amir R, Michaelis M, Devor M (1999). Membrane potential oscillations in dorsal root ganglion neurons: role in normal electrogenesis and neuropathic pain. J Neurosci 19:8559-8596.
2. Amir R, Michaelis M, Devor M (2002a). Burst discharge in primary sensory neurons: triggered by subthreshold oscillations, maintained by depolarizing afterpotentials. J Neurosci 22:1187-1198.
3. Amir R, Liu C-N, Kocsis JD, Devor M (2002b). Oscillatory mechanism in primary sensory neurons. Brain 125:421-435.
4. Backonja M (2001). Anticonvulsants and antiarrhythmics in the treatment of neuropathic pain syndromes. In: Hansson PT, Fields HL, Hill RG, Marchettini P, editors. Neuropathic pain: pathophysiology and treatment, progress in pain research and management (Vol 21). Seattle: IASP Press. pp. 285-1202
5. Belardinelli L, Shryock JC, Fraser H (2006). Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92:6-14.
6. Bennett GJ (1994). Neuropathic pain. In: Wall PD, Melzack R, editors. Textbook of pain (Vol 3). Edinburgh UK: Churchill Livingstone. pp. 201-224.
7. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB (2005). Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 19:CD003345.
8. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
9. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, et al. (2006). An SNC9A channelopathy causes congenital inability to experience pain. Nature 444:894-898.
10. Decosterd I, Woolf C (2000). Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87:149-158.
11. Devor M (2006). Sodium channels and mechanisms of neuropathic pain. J Pain 7:S3-S12.
12. Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, et al. (2005). Gain-of-function mutation in Nav 1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128:1847-1854.
13. v 1.7 and human pain disorders. Trends Neurosci 30:555-563.
14. Drenth JPH,Waxman SG (2007). Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 117:3603-3609.
15. + channel blockers in two rat models of neuropathic pain. Eur J Pharmacol 458:275-282.
16. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, et al. (2006). SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52:767-774.
17. Gil-Gouveia R, Goadsby PJ (2009). Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia 29:496-508.
18. V 1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71:311-319.
19. Gould HJ III, Gould TN, England JD, Paul D, Liu ZP, Levinson SR (2000). A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. Brain Res 854:19-29.
20. V 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. J Pain 5:270-280.
21. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA (2008). Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 44:954-967.
22. + channels in the developing mouse heart. J Physiol 564:683-696.
23. Intondi AB, Dhalgren MN, Eilers MA, Taylor BK (2008). Intrathecal neuropeptide Y reduces behavioral and molecular markers of inflammatory or neuropathic pain. Pain 137:352-365.
24. Ju YK, Gage PW, Saint DA (1996a). Tetrodotoxin-sensitive inactivation-resistant sodium channels in pacemaker cells influence heart rate. Pflugers Arch 431:868-875.
25. Ju YK, Saint DA, Gage PW (1996b). Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 497:337-347.
26. Koltzenburg M (1996). Afferent mechanisms mediating pain and hyperalgesias in neuralgia. In: Jä nig W, Stanton-Hicks M, editors. Reflex sympathetic dystrophy: a reappraisal, progress in pain research and management (Vol 6). Seattle: IASP Press. pp. 123-150.
27. Marx C, Sweeney M (2006). Mechanism of action of ranolazine. Arch Intern Med 166:1325-1326.
28. Nash DT (2005). The case for medical treatment in chronic stable coronary artery disease. Arch Intern Med 165:2587-2589.
29. v 1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 101:12706-12711.
30. Paul D, Gould HJ III, Dunne-Reilly A (2008). Predictive validity of a model of peripheral nerve demyelination-induced neuropathic pain. 12th World Congress on Pain Abstract:PW40.
31. Pham DQ, Mehta M (2007). Ranolazine: a novel agent that improves dysfunctional sodium channels. Int J Clin Pract 61:864-872.
32. + channels by ranolazine. Channels 2:449-460.
33. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, et al. (2008). Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 45:32-43.
34. Taylor BK, Abhyankar SS, Vo N-TT, Kriedt CL, Churi SB, Urban JH (2007). Neuropeptide Y acts at Y1 receptors in the rostral ventral medulla to inhibit neuropathic pain. Pain 131:83-95.
35. + channel isoforms by ranolazine. Mol Pharmacol 73:940-948.
36. Waxman SG (2006). A channel sets the gain on pain. Nature 444:831-832.
37. Zimmerman M (2001). Pathobiology of neuropathic pain. Eur J Pharmacol 429:23-37.